Global travel has made travel-associated infectious diseases (TAIDs) a more frequent consideration in the pediatric emergency department. Studies show that physicians may either omit a travel history or, even with a positive travel history, do not consider potentially serious illnesses, such as dengue and malaria. A thorough travel history including the purpose, location, activities, diet, and exposures can help the emergency clinician develop and narrow the differential diagnosis. This issue reviews the epidemiology, clinical presentation, diagnosis, and management of various TAIDs, with the goal of early recognition and disease-specific treatment.
How would you manage these patients? Subscribe for evidence-based best practices and to discover the outcomes.
Subscribe to access the complete flowchart to guide your clinical decision making.
Subscribe for full access to all Tables and Figures.
Following are the most informative references cited in this paper, as determined by the authors.
17. * Crowell CS, Stamos JK. Evaluation of fever after international travel. Pediatr Ann. 2011;40(1):39-44. (Review) DOI: 10.3928/00904481-20101214-09
20. * Flores MS, Hickey PW, Fields JH, et al. A “syndromic” approach for diagnosing and managing travel-related infectious diseases in children. Curr Probl Pediatr Adolesc Health Care. 2015;45(8):231-243. (Review) DOI: 10.1016/j.cppeds.2015.06.005
28. * Fox TG, Manaloor JJ, Christenson JC. Travel-related infections in children. Pediatr Clin North Am. 2013;60(2):507-527. (Review) DOI: 10.1016/j.pcl.2012.12.004
29. * Centers for Disease Control and Prevention. CDC Yellow Book 2020: Health Information for International Travel. New York, NY: Oxford University Press; 2020. (Textbook)
53. * Nield LS, Stauffer W, Kamat D. Evaluation and management of illness in a child after international travel. Pediatr Emerg Care. 2005;21(3):184-195. (Review) DOI: 10.1097/01.pec.0000161476.88453.04
57. Centers for Disease Control and Prevention. Treatment of malaria (guidelines for clinicians). Accessed October 15, 2021. (Online reference)
64. Centers for Disease Control and Prevention. Dengue. For healthcare providers. Clinical presentation. Accessed October 15, 2021. (Online reference)
67. Sharp TM. CDC Expert Commentary: differentiating chikungunya from dengue: a clinical challenge. Accessed October 15, 2021. (Online reference)
69. Centers for Disease Control and Prevention. Dengue. For health providers. Diagnosis. Accessed October, 15 2021. (Online reference)
90. Centers for Disease Control and Prevention. Chikungunya virus: clinical evaluation and disease. Accessed October, 15, 2021. (Online reference)
95. Centers for Disease Control and Prevention. Zika virus. For healthcare providers. Clinical evaluation & disease. Accessed October 15, 2021. (Online reference)
119. Centers for Disease Control and Prevention. Parasites - schistosomiasis; resources for health professionals. Accessed October 15, 2021. (Online reference)
130. U.S. Centers for Disease Control and Prevention. Antibiotic treatment. Recommendations for the use of antibiotics for the treatment of cholera. Accessed October 15, 2021. (CDC guideline)
Subscribe to get the full list of 130references and see how the authors distilled all of the evidence into a concise, clinically relevant, practical resource.
Keywords: travel-associated infections, travel-associated infectious diseases, TAID, travel history, traveler’s diarrhea, amebiasis, Middle East respiratory virus, MERS, cutaneous larva migrans, myiasis, tungiasis, leishmaniasis, cysticercosis, malaria, Plasmodium, uncomplicated malaria, severe malaria, malaria prophylaxis, malaria treatment, dengue, tourniquet test, dengue treatment, enteric fever, typhoid fever, paratyphoid fever, rose spots, enteric fever treatment, chikungunya, Zika, Zika virus, Zika virus infection, rickettsioses, Rocky Mountain spotted fever, Mediterranean spotted fever, African tick-bite fever, rickettsiosis treatment, schistosomiasis, blood trematodes, Katayama syndrome, schistosomiasis treatment, viral hemorrhagic fevers, Ebola, leptospirosis, leptospirosis treatment
David M. Walker, MD, FACEP, FAAP
Rabia Agha, MD; Nicolaus Glomb, MD, MPH
November 2, 2021
December 1, 2024
Date of Original Release: November 1, 2021. Date of most recent review: October 15, 2021. Termination date: November 1, 2024.
Accreditation: EB Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME.
Credit Designation: EB Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Specialty CME: Included as part of the 4 credits, this CME activity is eligible for 4 Infectious Disease CME and 1.5 Pharmacology CME credit, subject to your state and institutional requirements.
ACEP Accreditation: Pediatric Emergency Medicine Practice is also approved by the American College of Emergency Physicians for 48 hours of ACEP Category I credit per annual subscription.
AAP Accreditation: This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 48 AAP credits per year. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.
AOA Accreditation: Pediatric Emergency Medicine Practice is eligible for up to 48 American Osteopathic Association Category 2-A or 2-B credit hours per year.
Needs Assessment: The need for this educational activity was determined by a survey of medical staff, including the editorial board of this publication; review of morbidity and mortality data from the CDC, AHA, NCHS, and ACEP; and evaluation of prior activities for emergency physicians.
Target Audience: This enduring material is designed for emergency medicine physicians, physician assistants, nurse practitioners, and residents.
Goals: Upon completion of this activity, you should be able to: (1) demonstrate medical decision-making based on the strongest clinical evidence; (2) cost-effectively diagnose and treat the most critical ED presentations; and (3) describe the most common medicolegal pitfalls for each topic covered.
Discussion of Investigational Information: As part of the journal, faculty may be presenting investigational information about pharmaceutical products that is outside Food and Drug Administration approved labeling. Information presented as part of this activity is intended solely as continuing medical education and is not intended to promote off-label use of any pharmaceutical product.
Faculty Disclosures: It is the policy of EB Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME activities. All faculty participating in the planning or implementation of a CME activity are expected to disclose to the participants any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. In compliance with all ACCME accreditation requirements and policies, all faculty for this CME activity were asked to complete a full financial disclosure statement. The information received is as follows: Dr. Walker, Dr. Agha, Dr. Glomb, Dr. Mishler, Dr. Skrainka, Dr. Claudius, Dr. Horeczko, and their related parties report no relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) discussed in this educational presentation.
Commercial Support: This issue of Pediatric Emergency Medicine Practice did not receive any commercial support.
Earning Credit: Two Convenient Methods: (1) Go online to www.ebmedicine.net/CME and click on the title of this article. (2) Mail or fax the CME Answer And Evaluation Form with your June and December issues to Pediatric Emergency Medicine Practice.
Hardware/Software Requirements: You will need a Macintosh or PC with internet capabilities to access the website.
Additional Policies: For additional policies, including our statement of conflict of interest, source of funding, statement of informed consent, and statement of human and animal rights, visit https://www.ebmedicine.net/policies.